ClinicalTrials.gg
CompletedNCT01904292Updated Nov 20, 2017

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

A Phase 1 interventional study of Tocilizumab in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 42 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2017-11-20.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.

Enrollment
10th of 21
52 · median 52
Started
2013
with 4 others
Phase 1
4 of 21
none open now
Registered
15th of 21
by date
Lead sponsor
12 of 21
Hoffmann-La Roche

Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 10th largest by enrollment, is one of 5 that started in 2013, is one of 4 in phase 1, and was the 15th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tocilizumab in Arthritis, Juvenile, or all of them as a file.
02

Study summary

This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile Idiopathic Arthritis (sJIA). Participants with body weight less than (\<) 30 kilograms (kg) will receive subcutaneous (SC) tocilizumab dose every 2 weeks (Q2W) and participants with body weight greater than or equal to (>=) 30 kg will receive weekly (QW), for 52 weeks. Tocilizumab was administered every 10 days until pre-planned interim analysis was performed and changed to Q2W in participants with body weight \<30 kg.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of sJIA according to the International League of Associations for Rheumatology (ILAR) classification
  • History of inadequate clinical response (in the opinion of the treating physician) to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and
  • If a participant has received previous treatment with any biologic agents other than tocilizumab, these must have been discontinued according to the timelines defined by protocol prior to the baseline visit
  • Participants currently receiving tocilizumab by the intravenous (IV) route of administration and with well-controlled disease do not require a period of discontinuation of IV tocilizumab and should have their first dose of SC tocilizumab administered on the date that their next IV tocilizumab infusion would be due
  • Concurrent treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs) including methotrexate (MTX), NSAIDs, and oral corticosteroids are permitted at the discretion of the investigator
  • Participants of must be willing to use highly effective methods

Exclusion criteria

Exclusion Criteria:

  • Prior discontinuation of IV tocilizumab because of inadequate clinical response or safety events (including )
  • Participants with poorly controlled disease (in the opinion of the treating physician) despite current treatment with IV tocilizumab
  • sJIA that is well controlled by any treatment agent other than tocilizumab (Juvenile Arthritis Disease Activity Score of 71 Joints [JADAS-71] less than or equal to [\<=] 3.8 with no fever)
  • Participants who are wheelchair-bound or bedridden
  • Any other auto-immune, rheumatic disease, or overlapping syndrome other than sJIA
  • Lack of recovery from recent surgery or an interval of \<6 weeks since surgery at the time of the screening visit
  • Females who are pregnant, lactating, or intending to become pregnant during study conduct
  • Any significant concurrent medical or surgical condition that would jeopardize the participant's safety or ability to complete the study
  • Known (HIV) infection or other acquired forms of immune compromise or inborn conditions characterized by a compromised immune system
  • History of alcohol, drug, or chemical abuse within 6 months of screening
  • Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal infection or any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completed within 4 weeks of the screening visit or oral antibiotics completed within 2 weeks of the screening visit
  • History of atypical tuberculosis (TB) or active TB requiring treatment within 2 years prior to screening visit
  • Positive TB test at screening unless treated with anti-TB therapy for at least 4 weeks prior to receiving study drug
  • History of reactivation or new onset of a systemic infection such as herpes zoster or Epstein-Barr virus within 2 months of the screening visit
  • surface antigen or antibody positivity or chronic viral or hepatitis
  • History of concurrent serious gastrointestinal disorders such as ulcer or inflammatory bowel disease, Crohn's disease, ulcerative colitis, or other symptomatic lower gastrointestinal conditions
  • History of or current cancer or lymphoma
  • Uncontrolled diabetes mellitus with elevated glycosylated
  • Macrophage activation syndrome (MAS) within 3 months of the screening visit
  • Inadequate hematologic, renal or liver function
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Participants will receive SC dose of tocilizumab based on body weight; participants with \<30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =\>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.

    Drug: Tocilizumab

Interventions

  • Subcutaneous 162 mg dose QW or Q2W for 52 weeks

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Tocilizumab

    Time frame: Age <2 years: 0 hours(h) on Days(D) 0,84; on D5,14,42,70,85,88,98,182,266, 364. Weight <30kg, Age>=2 years: 0,6,12h on D0,84; on D2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight >=30kg: 0,6,12h on D0, 91; on D2,4,7,14,28,56,92,93,95,96,98,182,266, 364

  2. Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Tocilizumab

    Time frame: Age <2 years: 0h on D0,84; on D5,14,42,70,85,88,98,182,266,364. Weight <30 kg, Age >=2 years: 0,6,12h on D0,84; on D2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight >=30 kg: 0,6,12h on D0, 91; on D2,4,7,14,28,56,92,93,95,96,98,182,266,364

  3. Pharmacokinetics: Minimum Plasma Concentration (Cmin) of Tocilizumab

    Time frame: Weight <30 kg: predose (0h) on Days 0 and 84. Weight >= 30 kg: predose (0h) on Days 0 and 91

Secondary outcomes

  1. Pharmacodynamics: Serum Interleukin-6 (IL6) Levels

    Time frame: Age<2 years: 0h on Days 0,84; Days 5,14,42,70,85,88,98,182,266,364. Weight <30 kg, Age >=2 years: 0,6,12h on Days 0,84; Days 2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight >=30kg: 0,6,12h on Days 0,91;Days 2,4,7,14,28,56,92,93,95,96,98,182,266,364

  2. Pharmacodynamics: Soluble IL-6 Receptor (sIL-6R) Levels

    Time frame: Age<2 years: 0h on Days 0,84; Days 5,14,42,70,85,88,98,182,266,364. Weight <30 kg, Age >=2 years: 0,6,12h on Days 0,84; Days 2,5,14,42,56,70,86,87,88,90,98,182,266,364. Weight >=30kg: 0,6,12h on Days 0,91;Days 2,4,7,14,28,56,92,93,95,96,98,182,266,364

  3. Pharmacodynamics: Serum C-Reactive Protein (CRP) Levels

    Time frame: Age <2years: Days 0,14,28,42,70,84,98,126, 154,182,210,238,266,294,322,350,364. Weight <30 kg, Age >=2years: Days 0,14,28,42,70, 98,126,154,182,210,238,266,294,322,350,364. Weight >=30kg: Days 0,7,14,21,28,42, 56,70,84,91,95,96,98,182,266,294,322,350,364

  4. Pharmacodynamics: Serum Erythrocyte Sedimentation Rate (ESR)

    Time frame: Age <2years: Days 0,14,28,42,70,84,98,126, 154,182,210,238,266,294,322,350,364. Weight <30 kg, Age >=2years: Days 0,14,28,42,70, 98,126,154,182,210,238,266,294,322,350,364. Weight >=30kg: Days 0,7,14,21,28,42, 56,70,84,91,95,96,98,182,266,294,322,350,364

  5. Pharmacodynamics: Percentage of Participants with Anti-Tocilizumab Antibodies

    Time frame: Age <2 years: Days 0, 84, 182, 266, 364. Weight <30 kg, Age >=2 years: Days 0, 84, 182, 266, 364. Weight >=30 kg: Days 0, 91, 182, 266, 364

  6. Safety: Percentage of Participants with At Least 1 Adverse Event

    Time frame: 57 weeks

07

Study locations

42 sites
  • Arkansas Children's Hospital Research Institute
    Little Rock, Arkansas 72202, United States
  • Connecticut Children's Medical Center; 5E Clinical Trials Unit
    Hartford, Connecticut 06106, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago; Division of Rheumatology
    Chicago, Illinois 60611, United States
  • The University of Chicago;Department of Pediatrics
    Chicago, Illinois 60649, United States
  • Hackensack University Medical Center; Pediatric Rheumatology
    Hackensack, New Jersey 07601, United States
  • Levine Children's Hospital; Divison of Pediatric Rheumatology; Department of Pediatrics
    Charlotte, North Carolina 28203, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Cincinnati Children'S Hospital Medical Center; Division of Rheumatology
    Cincinnati, Ohio 45229-3039, United States
  • Cleveland Clinic Fndn
    Cleveland, Ohio 44195, United States
  • University of Utah; Immunology/Rheumatology/Allergy
    Salt Lake City, Utah 84109, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Hospital Gral de Niños Pedro Elizalde
    Buenos Aires, 1270, Argentina
  • Hospital de Ninos de la Santisima Trinidad; Reumatologia Infantil
    Cordoba, 5000, Argentina
  • Westmead Hospital; Paediatric Rheumatology
    Westmead, New South Wales 2145, Australia
  • Royal Children'S Hospital; Paediatric Rheumatology
    Parkville, Victoria 3052, Australia
  • Hospital das Clinicas - FMUSP Ribeirao Preto; Pediatria - Imunologia e Reumatologia
    Ribeirao preto., SP 14048-900, Brazil
  • Hospital das Clinicas - FMUSP; Instituto da Crianca - Reumatologia
    Sao Paulo, SP 05403-000, Brazil
  • Universidade Federal de Sao Paulo - UNIFESP
    Sao Paulo, SP 22793-080, Brazil
  • Alberta Children'S Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Children'S Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • Hospital For Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • CH de Bicêtre; Pediatrie Generale
    Le Kremlin Bicêtre, 94275, France
  • Charité Campus; Virchow Klinikum Berlin
    Berlin, 13353, Germany
  • Uniklinikum Freiburg Zentrum für Kinder- und Jugendmedizin; Pädiatrische Infektio- u. Rheumatologie
    Freiburg, 79106, Germany
  • Asklepios Klinik; Zentrum fuer Allgemeine Paediatrie und Neonatologie
    Sankt Augustin, 53757, Germany
  • Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina
    Roma, Lazio 00165, Italy
  • Istituto Giannina Gaslini-Ospedale Pediatrico IRCCS
    Genova, Liguria 16147, Italy
  • Nuovo Ospedale Pediatrico Meyer; Reumatologia - Clinica Pediatrica 1°
    Firenze, Toscana 50139, Italy
  • Hospital Infantil de México "Federico Gomez"; Rheumatology
    Mexico, 06720, Mexico
  • Cliditer SA de CV
    Miexico City, 06700, Mexico
  • Hospital Universitario Dr. Jose Eleuterio Gonzalez; Pediatria
    Monterrey, 64460, Mexico
  • FSBI "Scientific Research Institute of Rheumatology" of russian Academy of Medical Sciences
    Moscow, 115522, Russian Federation
  • SI Sceintific children health center RAMS
    Moscow, 119991, Russian Federation
  • Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica
    Esplugas DE Llobregat, Barcelona 08950, Spain
  • Hospital Infantil Universitario Niño Jesus, Servicio Reumatologia
    Madrid, 28009, Spain
  • Hospital Ramon y Cajal ; Servicio de Reumatologia
    Madrid, 28034, Spain
  • Hospital de La Paz; Unidad de Reumatologia Pediatrica
    Madrid, 28046, Spain
  • Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica
    Valencia, 46026, Spain
  • Bristol Royal Hospital For Children
    Bristol, BS2 8BJ, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, L12 2AP, United Kingdom
  • Great Ormond Street Hospital; Somers Clinical Research Facility
    London, WC1N 3JH, United Kingdom
  • Nottingham Children's Hospital
    Nottingham, NG7 2UH, United Kingdom
08

References and documents

Publications

  • Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Perez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, Benedetti F; Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG). Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Oct 2;60(10):4568-4580. doi: 10.1093/rheumatology/keab047. PubMed 33506875 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2013 to primary completion in Jun 2017, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2013
First posted
Jul 22, 2013
StartActual
Aug 15, 2013
Primary completionActual
Jun 13, 2017
CompletionActual
Jun 13, 2017
Last update
Nov 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01904292
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 22, 2013
Start date
Aug 15, 2013
Primary completion
Jun 13, 2017
Completion
Jun 13, 2017
Last update
Nov 20, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion